Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Shelly Sakiyama-Elbert

Washington University, Department: Orthopedics

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

Kuros Therapeutics

Disclosed Value
Listed Reason
Intellectual property rights (e.g., royalties, patents, copyrights) not from the awardee Institution

Based on Washington University’s Research COI Policy and the Procedures for Determining and Managing Research Financial Conflicts of Interests, Washington University determined Dr. Sakiyama-Elbert’s personal financial relationship with Kuros Therapeutics, related to the above referenced research creates a financial conflict of interest due to the following reasons:

• Dr. Sakiyama-Elbert’s personal financial relationships are directly related to the research because the study is utilizing technology from Dr. Sakiyama-Elbert’s intellectual property, which is licensed by Kuros Therapeutics.

• If the results are favorable, this study could impact the value of the intellectual property, which could increase the value of Dr. Sakiyama-Elbert’s personal financial interest with Kuros Therapeutics.

• Dr. Sakiyama-Elbert’s role in design of the study, collection, analysis and review of the data, and in reporting the results could directly affect the outcome of the study.

Listed Research Project
Enhanced Tendon Healing through Growth Factor and Cell Therapies

Treatment of musculoskeletal injuries results in 30 billion dollars in healthcare costs in the United States each year. Approximately half of these injuries involve tendons and ligaments. Growth factor- and cell- based therapy has the potential to improve healing for a broad range of connective tissue injuries. Our long-term goal is to apply growth factor and cell therapy solutions in order to positively affect the clinical outcomes of tendon repair.

Filed on July 31, 2013.

Tell us what you know about Shelly Sakiyama-Elbert's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page